Sun Yat-sen University: Carcinoma, Renal Cell trials

The registry lists 12 Carcinoma, Renal Cell studies with Sun Yat-sen University as lead sponsor. 8 are open to participants now and 0 have results posted.

Phase 1 1Phase 2 7Phase 3 1No phase 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Ischemic Preconditioning Reduces the Severity of Acute Kidney Injury After Partial NephrectomyNot yet recruitingNCT07497958Not applicable
• Safety and Efficacy of Yiwoxidan Anti (AK112) Monotherapy in Patients With Metastatic Renal Clear Cell Carcinoma Who Are Intolerant to TKI Treatment: a Prospective, Single Arm, Phase II Clinical StudyEnrolling by invitationNCT07488572Phase 2
• Iparomlimab and Tuvonralimab (QL1706) Combination With Lenvatinib as Neoadjuvant Therapy for ccRCCRecruitingNCT07389629Phase 2
• Pucotenlimab Combination With Vorolanib as Neoadjuvant Therapy for ccRCCRecruitingNCT07386158Phase 2
• The Cold Ischemia Robot-assisted Partial NephrectomyRecruitingNCT07326280Not applicable
• An Exploratory Study on the Failure of Immunotherapy With Vorolanib Combined With EverolimusRecruitingNCT06730672Phase 2
• Systemic Therapy Alone or With Stereotactic Body Radiotherapy for Oligometastatic Kidney Cancer (STROKER Study)RecruitingNCT06726421Phase 3
• Pucotenlimab Combined With Lenvatinib as a Neodjuvant Therapy for Non Clear Cell Renal Cell CarcinomaNot yet recruitingNCT06129955Phase 2
• Cadonilimab Combination With Lenvatinib as Neoadjuvant Therapy for ccRCCCompletedNCT06138496Phase 2
• Exploring the Influence of Clinical Factors on the Prognosis of Papillary Renal Cell CarcinomaCompletedNCT06111560
• A Study of Combinations of D-CIK Immunotherapy And Anti-PD-1 In Refractory Solid TumorsStatus unknownNCT02886897Phase 1/2
• microRNA Expression in Renal Cell CarcinomaCompletedNCT00743054